Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I remember

<< Previous

Bullboard Posts

Next >>

Post by Zartoshison Apr 12, 2024 12:55am

1805 Views

Post# 35984864

I remember

I was here 2 years ago when this stock first crashed down to $1.5.

Still remember bugsy, mugs, duster and a couple others.

i know you guys lost a lot of money on this stock, but worst of all, you guys lost a lot of time! Can't believe you're all still here after all these years.. you can never get that time back,

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price